Adverse event
|
Famitinib alone
|
Famitinib with CCRT
|
---|
Grade 1–2
|
Grade 3
|
Grade 4
|
Grade 5
|
Total
|
Grade 1–2
|
Grade 3
|
Grade 4
|
Grade 5
|
Total
|
---|
Leukopenia
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
2 (10%)
|
17 (85%)
|
1 (5%)
|
0
|
20 (100%)
|
Neutropenia
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
9 (45%)
|
10 (50%)
|
1 (5%)
|
0
|
20 (100%)
|
Anaemia
|
2 (10%)
|
0
|
0
|
0
|
2 (10%)
|
16 (80%)
|
4 (20%)
|
0
|
0
|
20 (100%)
|
Radiation mucositis
|
0
|
0
|
0
|
0
|
0
|
16 (80%)
|
3 (15%)
|
1 (5%)
|
0
|
20 (100%)
|
Nausea and vomiting
|
0
|
0
|
0
|
0
|
0
|
16 (80%)
|
1 (5%)
|
0
|
0
|
17 (85%)
|
Radiation dermatitis
|
0
|
0
|
0
|
0
|
0
|
13 (65%)
|
0
|
0
|
0
|
13 (65%)
|
Weight loss
|
0
|
0
|
0
|
0
|
0
|
15 (75%)
|
0
|
0
|
0
|
15 (75%)
|
Proteinuria
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
15 (75%)
|
1 (5%)
|
0
|
0
|
16 (80%)
|
Thrombopenia
|
0
|
0
|
0
|
0
|
0
|
10 (50%)
|
3 (15%)
|
1 (5%)
|
0
|
14 (70%)
|
Hypertension
|
3 (15%)
|
0
|
0
|
0
|
3 (15%)
|
8 (40%)
|
1 (5%)
|
0
|
0
|
9 (45%)
|
Liver function impairment
|
3 (15%)
|
0
|
0
|
0
|
3 (15%)
|
10 (50%)
|
1 (5%)
|
0
|
0
|
11 (55%)
|
Hypertriglyceridemia
|
5 (25%)
|
0
|
0
|
0
|
5 (25%)
|
5 (25%)
|
0
|
0
|
0
|
5 (25%)
|
Hearing impairment
|
0
|
0
|
0
|
0
|
0
|
4 (20%)
|
0
|
0
|
0
|
4 (20%)
|
Renal impairment
|
0
|
0
|
0
|
0
|
0
|
4 (20%)
|
0
|
0
|
0
|
4 (20%)
|
Hematuria
|
2 (10%)
|
1 (5%)
|
0
|
0
|
3 (15%)
|
4 (20%)
|
1 (5%)
|
0
|
0
|
5 (25%)
|
Haemorrhage
|
0
|
0
|
0
|
0
|
0
|
2 (10%)
|
0
|
0
|
0
|
2 (10%)
|
Skin rash
|
2 (10%)
|
0
|
0
|
0
|
2 (10%)
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
Hypothyroidism
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Hypercholesterolemia
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
0
|
0
|
0
|
0
|
0
|
Elevated total bilirubin
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
1 (5%)
|
0
|
0
|
0
|
1 (5%)
|
Elevated GGT
|
2 (10%)
|
0
|
0
|
0
|
2 (10%)
|
2 (10%)
|
0
|
0
|
0
|
2 (10%)
|
- CCRT concurrent chemoradiotherapy, GGT gamma glutamyl transpeptidase, NPC nasopharyngeal carcinoma